Taliglucerase alfa

Drug Profile

Taliglucerase alfa

Alternative Names: Alfataliglicerase; Elelyso; Glucocerebrosidase; Oral GCD; prGCD; PRX-112; Uplyso

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Protalix Biotherapeutics
  • Developer Pfizer; Protalix BioTherapeutics
  • Class Glucosidases; Recombinant proteins
  • Mechanism of Action Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gaucher's disease

Most Recent Events

  • 11 Jan 2017 Pfizer plans a phase IV trial for Gaucher's disease (In children) in USA (IV, Infusion) (NCT03021941)
  • 22 Nov 2016 Launched for Gaucher's disease (In adolescents, In children) in Brazil (IV)
  • 22 Nov 2016 Registered for Gaucher's disease (In children, In adolescents) in Brazil (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top